Study of GNX102 in Patients With Advanced Solid Tumors

计划入组 46 人 · 首次发布于 2020 年 1 月 31 日

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

计划入组 150 人 · 首次发布于 2025 年 8 月 28 日

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

计划入组 160 人 · 首次发布于 2024 年 10 月 18 日

masked ADC

PSMA-ADC-1301

ADC-001

ADC Therapeutics

Switzerland

ADC Therapeutics America, Inc.

United States

Lophora ApS

Denmark

GlycoNex Partners with Sterling for GNX102-ADC Clinical Trial Production

GlycoNex Partners with Sterling for GNX102-ADC Clinical Trial Manufacturing

GlycoNex Advances Novel Glycan-Targeted ADC GNX1021 for HER2-Low Gastric Cancer